RxDoctor Payments Data

Graeme Reed, MD

Family Medicine · Colton, CANPI 1609105162

Payments from drug & device makers

$2,446in general payments, 2019–2025

Across 119 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$389
  • Bayer$377
  • AstraZeneca$351
  • AbbVie$292
  • Lilly USA, LLC$234
  • Novo Nordisk$190
  • plus $613 from 8 others

What the payments were for

  • Food & beverage$2,43399%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,446 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$26,272
Medicare patients
62
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$67,855
KerendiaFinerenone38$49,354
OzempicSemaglutide29$41,970
RybelsusSemaglutide14$29,981
JanuviaSitagliptin Phosphate18$18,907
Breo ElliptaFluticasone/Vilanterol15$5,927
Testosterone11$2,352
Atorvastatin Calcium115$2,338
Rosuvastatin Calcium68$2,284
Levothyroxine Sodium82$2,046
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,908
Morphine Sulfate ErMorphine Sulfate26$1,095
Losartan Potassium64$1,084
Oxycodone Hcl26$872
Lisinopril56$674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$190$71,95243 claims
Boehringer IngelheimJardiance$122$67,85547 claims
BayerKerendia$377$49,35438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →